IMNN

Imunon, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website imunon.com
Employees(FY) 31
ISIN US15117N6022

Performance

-11.78%

-30.59%

-43.47%

-51.14%

+0.59%

YTD

-26.48%

Profile

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Advanced Technical Analysis

Technical Analysis of IMNN 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declin...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IMNN

Stock Rank

Recent News & Updates

2024-11-07 13:23
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...(Yahoo Finance)
2024-11-06 21:00
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting(Globenewswire)
2024-11-06 19:05
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-10-30 20:30
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024(Globenewswire)
2024-10-29 21:05
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting(Globenewswire)
2024-10-07 20:45
Imunon reports inducement grant under NASDAQ listing rule(Yahoo Finance)
2024-10-06 20:05
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)(Globenewswire)
2024-09-09 04:06
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management(Globenewswire)
2024-09-08 20:30
IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management(Globenewswire)
2024-08-27 20:30
IMUNON to Host R&D Day on September 18th(Globenewswire)
2024-08-13 20:00
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-08-07 05:04
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024(Globenewswire)
2024-07-30 23:54
Imunons shares soar after IL-12 therapy success in Phase II trial(Yahoo Finance)
2024-07-30 20:00
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules(Globenewswire)
2024-07-29 20:00
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001(Globenewswire)
2024-07-29 04:05
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow(Globenewswire)
2024-06-23 20:30
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer(Globenewswire)
2024-06-04 20:30
First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial(Globenewswire)
2024-05-14 20:30
Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting(Globenewswire)
2024-05-13 18:08
Q1 2024 Imunon Inc Earnings Call(Yahoo Finance)
2024-05-13 15:02
Imunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...(Yahoo Finance)
2024-05-13 00:52
IMNN Stock Earnings: Imunon Beats EPS for Q1 2024(Investorplace)
2024-05-12 21:00
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study(Globenewswire)
2024-05-12 20:00
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-05-07 20:00
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO(Globenewswire)
2024-05-05 23:00
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024(Globenewswire)
2024-04-17 20:30
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101(Globenewswire)
2024-04-10 20:00
IMUNON Reports Compliance with Nasdaq Listing Requirements(Globenewswire)
2024-04-01 07:08
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript(Yahoo Finance)
2024-03-28 00:52
IMNN Stock Earnings: Imunon Beats EPS for Q4 2023(Investorplace)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.